Dysfunctional endothelium contributes to more diseases than any other tissue in the body.
Small interfering RNAs (siRNAs) can help in the study and treatment of endothelial cells in …

Dysfunctional endothelial cells contribute to the pathophysiology of many diseases,
including vascular disease, stroke, hypertension, atherosclerosis, organ failure, diabetes …

Human endothelial cells are initiators and targets of the rejection response. Pre-operative
modification of endothelial cells by small interfering RNA transfection could shape the nature …

RNA interference (RNAi) entails the potential for novel therapeutic strategies through the
silencing of disease-causing genes in vivo. However, recent studies have raised an issue …

RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in
cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated …

The development of controlled-release nanoparticle (NP) technologies has great potential to
further improve the therapeutic efficacy of RNA interference (RNAi), by prolonging the …

For the application of RNA interference (RNAi) in vivo the functional delivery of short
interfering RNAs (siRNAs) is still the major obstacle. Therefore, delivery technologies need …

A small percentage of the short interfering RNA (siRNA) delivered via passive lipid
nanoparticles and other delivery vehicles reaches the cytoplasm of cells. The high doses of …

Macrophages in atherosclerotic lesions promote plaque progression and are an attractive
therapeutic target in cardiovascular research. Here we present a protocol for synthesis of …

Posttranscriptional gene silencing by RNA interference can be therapeutically exploited to
inhibit pathophysiological gene expression. However, in contrast to the established …